Haematologica, Vol 93, Issue 1, 124-127 doi:10.3324/haematol.11644
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Errata Corrige
Right arrow Erratum (v93,p480)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (28)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lokhorst, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lokhorst, H. M.

Multiple Myeloma

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst1,, Ingo Schmidt-Wolf2, Pieter Sonneveld1, Bronno van der Holt1, Hans Martin2, Rene Barge1, Uta Bertsch2, Jana Schlenzka2, Gerard M.J. Bos1, Sandra Croockewit1, Sonja Zweegman1, Iris Breitkreutz2, Peter Joosten1, Christof Scheid2, Marinus van Marwijk-Kooy1, Hans-Juergen Salwender2, Marinus H.J. van Oers1, Ron Schaafsma1, Ralph Naumann2, Harm Sinnige1, Igor Blau2, Michel Delforge1, Okke de Weerdt1, Pierre Wijermans1, Shulamiet Wittebol1, Ulrich Duersen2, Edo Vellenga1, Hartmut Goldschmidt1 for Dutch-Belgian HOVON and German GMMG

1Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2German GMMG

Correspondence: H.M. Lokhorst, Dept. of Hematology, University Medical Center, Utrecht, The Netherlands. E-mail: h.lokhorst{at}umcutrecht.nl

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3–4 adverse events were similar in both arms.

Key words: thalidomide, untreated multiple myeloma.




This article has been cited by other articles:


Home page
 The OncologistHome page
H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al.
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Oncologist, January 1, 2010; 15(1): 6 - 25.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Stewart, P. G. Richardson, and J. F. San-Miguel
How I treat multiple myeloma in younger patients
Blood, December 24, 2009; 114(27): 5436 - 5443.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al.
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood, October 8, 2009; 114(15): 3139 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams
Initial therapy in multiple myeloma: investigating the new treatment paradigm
Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 131 - 141.
[Abstract] [PDF]

Home page
 BloodHome page
S. Kumar, S. Giralt, E. A. Stadtmauer, J. L. Harousseau, A. Palumbo, W. Bensinger, R. L. Comenzo, S. Lentzsch, N. Munshi, R. Niesvizky, et al.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Blood, August 27, 2009; 114(9): 1729 - 1735.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. F. San-Miguel and M.-V. Mateos
How to treat a newly diagnosed young patient with multiple myeloma
Hematology, January 1, 2009; 2009(1): 555 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J.-L. Harousseau
Induction Therapy in Multiple Myeloma
Hematology, January 1, 2008; 2008(1): 306 - 312.
[Abstract] [Full Text] [PDF]